BioMarin Pharmaceutical Inc. (LON:0HNC)
58.00
-1.30 (-2.19%)
At close: Jul 31, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $745.15M USD in the quarter ending March 31, 2025, with 14.84% growth. This brings the company's revenue in the last twelve months to $2.95B, up 19.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$2.95B
Revenue Growth
+19.36%
P/S Ratio
3.69
Revenue / Employee
$970.47K
Employees
3,040
Market Cap
8.42B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
BioMarin Pharmaceutical News
- 9 days ago - BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha
- 9 days ago - What Does the Market Think About BioMarin Pharmaceutical? - Benzinga
- 10 days ago - BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - PRNewsWire
- 4 weeks ago - BioMarin Announces Completion of Acquisition of Inozyme - PRNewsWire
- 5 weeks ago - BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress - PRNewsWire
- 7 weeks ago - Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga
- 7 weeks ago - Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer - CNBC
- 2 months ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire